Bristol Myers gets regulatory approval for anemia drug Reblozyl, secures FDA label expansion

Bristol Myers Squibb has scored another win for its anemia drug Reblozyl, revealing Monday evening the FDA granted the drug its third indication.

The FDA approved the drug as a frontline treatment for adult anemia patients with lower-risk myelodysplastic syndromes (MDS) who may require red blood cell transfusions, and who also had not used erythropoiesis-stimulating agents, or ESAs.

The agency accepted an sNDA for the drug back in May, granting it priority review.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。